302 related articles for article (PubMed ID: 31783815)
1. Clinicopathological features, survival and risk in breast cancer survivors with thyroid cancer: an analysis of the SEER database.
Li S; Yang J; Shen Y; Zhao X; Zhang L; Wang B; Li P; Wang Y; Yi M; Yang J
BMC Public Health; 2019 Nov; 19(1):1592. PubMed ID: 31783815
[TBL] [Abstract][Full Text] [Related]
2. Risk of second primary thyroid cancer in cancer survivors.
Yuan Y; Sun P; Xiao H; Li L; Li J; Ai X
Sci Rep; 2024 May; 14(1):12478. PubMed ID: 38816510
[TBL] [Abstract][Full Text] [Related]
3. Risk and survival of chronic myeloid leukemia after breast cancer: A population-based study.
Al-Husseini MJ; Mohamed HH; Saad AM; Gad MM; Atia M; Qaddoora U; Abushouk AI; El-Shinawi M
Curr Probl Cancer; 2019 Jun; 43(3):213-221. PubMed ID: 30195804
[TBL] [Abstract][Full Text] [Related]
4. Risk of second primary breast cancer among cancer survivors: Implications for prevention and screening practice.
Cheng Y; Huang Z; Liao Q; Yu X; Jiang H; He Y; Yao S; Nie S; Liu L
PLoS One; 2020; 15(6):e0232800. PubMed ID: 32497148
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer prognosis is better in patients who develop subsequent metachronous thyroid cancer.
Lei K; He X; Yu L; Ni C; Chen H; Guan D; Sun K; Zou H
PLoS One; 2019; 14(5):e0215948. PubMed ID: 31042767
[TBL] [Abstract][Full Text] [Related]
6. Thyrotropin suppression therapy using levothyroxine does not negatively affect breast cancer prognosis.
He X; Zhong M; Zhang Q; Aierken N; Cui L; Xing Z; Lei K
Cancer Treat Res Commun; 2022; 31():100525. PubMed ID: 35114502
[TBL] [Abstract][Full Text] [Related]
7. Decreased breast cancer-specific mortality risk in patients with a history of thyroid cancer.
Cheng W; Shen X; Xing M
PLoS One; 2019; 14(10):e0221093. PubMed ID: 31644578
[TBL] [Abstract][Full Text] [Related]
8. A population-based study of prognosis and survival in patients with second primary thyroid cancer after Hodgkin lymphoma.
Chowdhry AK; Fung C; Chowdhry VK; Bergsma D; Dhakal S; Constine LS; Milano MT
Leuk Lymphoma; 2018 May; 59(5):1180-1187. PubMed ID: 28862484
[TBL] [Abstract][Full Text] [Related]
9. The clinical and genetic features in patients coexisting primary breast and thyroid cancers.
Fu J; He M; Wu Q; Zhang X; Qi X; Shen K; Wang X; Zhang G
Front Endocrinol (Lausanne); 2023; 14():1136120. PubMed ID: 37229458
[TBL] [Abstract][Full Text] [Related]
10. Risk of Second Primary Female Genital Malignancies in Women with Breast Cancer: a SEER Analysis.
Li Z; Wu Q; Song J; Zhang Y; Zhu S; Sun S
Horm Cancer; 2018 Jun; 9(3):197-204. PubMed ID: 29556910
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and survival of patients with metachronous or synchronous double primary malignancies: breast and thyroid cancer.
Zhang L; Wu Y; Liu F; Fu L; Tong Z
Oncotarget; 2016 Aug; 7(32):52450-52459. PubMed ID: 27223440
[TBL] [Abstract][Full Text] [Related]
12. Survival of Patients with First and Metachronous Second Primary Breast Cancer or Lung Cancer Malignancy: Comparisons Using the SEER Database.
Zhong M; He X; Lei K
Adv Ther; 2020 May; 37(5):2236-2245. PubMed ID: 32274747
[TBL] [Abstract][Full Text] [Related]
13. A Possible Association Between Thyroid Cancer and Breast Cancer.
An JH; Hwangbo Y; Ahn HY; Keam B; Lee KE; Han W; Park DJ; Park IA; Noh DY; Youn YK; Cho BY; Im SA; Park YJ
Thyroid; 2015 Dec; 25(12):1330-8. PubMed ID: 26442580
[TBL] [Abstract][Full Text] [Related]
14. Inducing or Preventing Subsequent Malignancies for Breast Cancer Survivors? Double-edged Sword of Estrogen Receptor and Progesterone Receptor.
Hu ZY; Xiao H; Xiao M; Tang Y; Sun J; Xie ZM; Ouyang Q
Clin Breast Cancer; 2018 Oct; 18(5):e1149-e1163. PubMed ID: 29885789
[TBL] [Abstract][Full Text] [Related]
15. The co-occurrence of both breast- and differentiated thyroid cancer: incidence, association and clinical implications for daily practice.
Piek MW; de Boer JP; van Duijnhoven F; van der Wal JE; Vriens M; van Leeuwaarde RS; van der Ploeg IMC
BMC Cancer; 2022 Sep; 22(1):1018. PubMed ID: 36163009
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features, risk and survival in lung cancer survivors with therapy-related acute myeloid leukaemia.
Wang H; Yin Y; Wang R; Huang J; Xue H; Cheng Y; Zhang L; Chen C
BMC Cancer; 2020 Nov; 20(1):1081. PubMed ID: 33172389
[TBL] [Abstract][Full Text] [Related]
17. Racial and ethnic differences in risk of second primary cancers among breast cancer survivors.
Calip GS; Law EH; Ko NY
Breast Cancer Res Treat; 2015 Jun; 151(3):687-96. PubMed ID: 26012645
[TBL] [Abstract][Full Text] [Related]
18. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis.
Liu J; Jiang W; Mao K; An Y; Su F; Kim BY; Liu Q; Jacobs LK
Breast Cancer Res Treat; 2015 Apr; 150(2):439-45. PubMed ID: 25764167
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Factors for Metachronous Contralateral Breast Cancer: Implications for Management of the Contralateral Breast.
Marmor S; Portschy PR; Burke EE; Virnig BA; Tuttle TM
Breast J; 2017 May; 23(3):299-306. PubMed ID: 27988977
[TBL] [Abstract][Full Text] [Related]
20. Age at Primary Malignancy Determines Survival in Adolescent and Young Adults That Develop a Secondary Thyroid Cancer.
Lau BJ; Goldfarb M
J Adolesc Young Adult Oncol; 2016 Jun; 5(2):201-8. PubMed ID: 27042962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
